PER 13.5% 6.4¢ percheron therapeutics limited

Nice post Maxi, I'm also top 20 and share your dream of...

  1. 960 Posts.
    lightbulb Created with Sketch. 322
    Nice post Maxi, I'm also top 20 and share your dream of retirement within 2 years. I have more confidence in ANP succeeding than any other stock I have previously owned. The company is perfectly positioned with great results for DMD and patents pending for a number of other indications. The real PR will begin once patents are awarded. Even if they only pick up 5% of the $100B per year global inflammation market, the thought of $5B per year cash flow will see us well above the $5 per share or already taken over by big Pharma. So why are we still at 20 cents? Sure funding is still uncertain but my guess is that Platinum is close to gone and when selling is finished will see a rapid share price rise to true value of at least 40 cent within the next 6 months. Huge congrats to Mark and the board for bringing in such a stellar line up of expertise to take this product to market. As you have suggested no way have the new recruits come on board to fail. I'm just surprised that they haven't taken significant shareholder positions given that they would all be very wealthy in their own right by now. Maybe sometimes it's just about giving back to the community and in this case helping out these poor boys and their families. Ignore the negative sentiments on this forum, patience is a virtue and those who hold out will be well rewarded...
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
6.4¢
Change
-0.010(13.5%)
Mkt cap ! $57.69M
Open High Low Value Volume
7.4¢ 7.6¢ 5.9¢ $516.4K 8.992M

Buyers (Bids)

No. Vol. Price($)
2 339429 6.4¢
 

Sellers (Offers)

Price($) Vol. No.
7.6¢ 143169 1
View Market Depth
Last trade - 16.10pm 25/04/2024 (20 minute delay) ?
Last
5.9¢
  Change
-0.010 ( 21.3 %)
Open High Low Volume
7.6¢ 7.6¢ 5.9¢ 132018
Last updated 15.49pm 25/04/2024 ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.